Xeris Biopharma price target raised to $6.60 from $6 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on Xeris Biopharma (XERS) to $6.60 from $6 and keeps a Buy rating on the shares. The company reported a big Q3 beat excluding GAAP non-cash items as its growth assets are outperforming, the analyst tells investors in a research note.